"The main advantages of the proposed technology to be developed is the additional clinically relevant information that it provides (i.e. in addition to blood oxygenation, it measures cerebral blood flow (CBF), cerebral blood volume (CBV), oxygen extraction fraction (OEF) and metabolism (CMRO2)), improved accuracy, performance and usability, competitiveness against other available technologies (i.e. against other modalities for similar parameters) and the potential to be utilized in larger populations due to its non-invasive and safe nature (out-patient, paediatrics etc). Through this project, we will are aiming to introduce new capabilities to medical devices developed and produced in Europe.
The development of a new prototype and its initial clinical validation for future commercialization is the key aspect of this project. By working closely with our partners to understand, develop and validate the technology we will differentiate ourselves from the ""traditional"" research prototypes that do not make it into the clinic.
We believe we are looking into the future with the highest information content for absolute value measurements and the potential to separate intra- and extra-cerebral contributions. By combining Time Resolved Spectroscopy (TRS) with Diffuse Correlation Spectroscopy (DCS), we have introduces two new parameters, namely the cerebral blood flow (CBF) and cerebral metabolic rate of oxygen extraction (CMRO2), which may enable a better understanding of the physiological status of the brain.
We have built upon the experience gained in our EU funded projects, and through collaboration of partners and ESRs started to develop TRS into a viable instrument for bedside monitoring in neurocritical care. At the sub-system level, we have made key advances in opto-electronics for Time Resolved Spectroscopy.
We have made advances in Diffuse Correlation Spectroscopy technology at sub-systems level by introducing new opto-electronic components. These are now being integrated into a system where we expect improvements in SNR in stability and clinical usability and accuracy.
We have increased our ability in computational tools for modeling and data analysis by incorporating the tools and algorithms for diffuse correlation spectroscopy and tomography. We have already addressed two important aspects that will facilitate the translation to the clinic: (1) complete automation of image segmentation and model generation; (2) implementation on multi-core and GPU hardware for high-speed reconstruction.
"